How combining drugs may be more effective at treating HER2-positive breast cancer

Elena Shagisultanova, MD, PhD's groundbreaking research focuses on HER2-positive breast cancer, a subtype that disproportionately affects young women. Her innovative “triple-block” approach combines targeted therapies to counter drug resistance and improve treatment outcomes.